Cell 2025 Logo (Light)

11 - 12 November 2025 | London, UK

Connecting Leaders From Every Stage of the Value Chain to Drive Advanced Therapy Development & Novel Biologics Processing

Overview Cell & Gene Therapy Manufacturing Advanced Therapy Development Cell Culture & Bioprocessing

Welcome to Cell 2025, Oxford Global’s flagship event bringing together leaders from pharma, biotech, academia, and regulatory institutions across the entire cell culture and cell & gene therapy value chain.

From discovery and development to manufacturing, supply chain, logistics, and commercialisation, our agenda covers every critical stage. Featuring the Cell Culture & Bioprocessing, Advanced Therapy Development, and Cell & Gene Therapy Manufacturing programmes, this event is jam-packed with cutting-edge presentations, C-level discussions, technology & investor showcases, and unparalleled networking opportunities. Dive into pioneering strategies and innovative technologies driving the future of advanced therapies. Don’t miss out on staying ahead of breakthrough advancements set to shape the cell culture and cell & gene therapy markets. 

Cell & Gene Therapy Manufacturing

  • Hear from and meet with the key innovators in cell & gene therapy manufacturing. 2024 attendees included: Director Product Supply Cell & Gene, BioNTech SE; Vice President, Clinical Strategy and Development, Medigene; Chief Scientific Officer, CellProthera
  • Take a deep dive into strategies for gene therapy manufacturing. Key opinion leaders will cover the challenges associated with scale-up, utilising single-use technologies and sustainable manufacturing practices
  • Benefit from the latest development in supply chain & logistics. Presentations will address regulatory compliance in transportation, shipping & tracking of new modalities in the clinic & collaborations across the supply chain
  • Explore strategies for cell therapy manufacturing with topic areas such as autologous vs allogenic products, automation & digitalisation, transitioning from R&D to clinical manufacturing & the path towards commercialisation
  • Take advantage of a wide range of interactive sessions onsite. 2024 panel discussions included: ‘Strategies For Navigating Evolving Regulatory Landscapes’; ‘CGT IP Challenges & Strategies’; ‘How To Troubleshoot Cell Line Engineering & Development Bottlenecks’ and many more 

Agenda at a Glance


Day One

Track 1: Strategies for Gene Therapy Manufacturing
Track 2: Supply Chain & Logistics 

Day Two

Track 1: Strategies for Cell Therapy Manufacturing  

Advanced Therapy Development

  • New to 2025! Take a deep dive into regulatory considerations for cell & gene therapies. Key opinion leaders will be covering the regulations surrounding the development of platforms for genetically modified B cells and using accelerated regulatory pathways
  • New to 2025! Gain invaluable insights into tissue engineering development, with presentations addressing stem cells for cartilage, biomaterials for tissue engineering and tissue engineering with different cell types

Agenda at a Glance


Day One

Track 1: Novel Strategies for Gene Therapy Discovery & Development
Track 2: Cell & Gene Therapy Analytics & Quality Control
Track 4: Tissue Engineering Development

Day Two

Track 1: CGT Clinical Development & Clinical Trials
Track 2: Cell Therapy Development
Track 3: iPSCs and Stem Cell Therapy Development
Track 4:
Regulatory Considerations & Commercialisation for Cell & Gene Therapies

 

Cell Culture & Bioprocessing

  • Hear from and meet with the key innovators in cell culture & bioprocessing. 2024 attendees included: Chief Scientific Officer, Medigene AG; Senior Vice President, Global Regulatory Affairs, BioNTech SE
  • New to 2025! Gain invaluable insights into innovations in pre-clinical assay development & 3D cell cultures. Key opinion leaders will be addressing the integration of iPSC models for pre-clinical studies, 2D versus 3D cultures and case studies highlighting pre-clinical successes and failures
  • New to 2025! Take a deep dive into the latest strategies for enabling successful cell line engineering – improving efficiency and removing bottlenecks in cell line development, screening clones for productivity and titer & predicting and characterising clones
  • Devised with the help of our esteemed advisory board. Key presentations will cover gene delivery in drug discovery, automation & digitalisation in bioprocessing and techniques for enhancing cell culture productivity
  • New to 2025! Join thought-leader panel discussions, investor-focused sessions and roundtables pertaining to the latest in cell culture & bioprocessing

Agenda at a Glance


Day One

Track 1: Cell Line Engineering Ensuring Stability, Quality & Clonality
Track 2: Upstream & Downstream Bioprocessing: Novel Technologies & Continuous Processing

Day Two

Track 1: Gene Delivery & Gene Editing for Cell Line Development  
Track 2: Innovations in Pre-Clinical Assay Development, Cell Culture Media Optimization & 3D Cultures: From In Vitro Models to Translational Success

What to Expect at Cell 2025

Networking & knowledge-sharing is at the heart of what we do, with 230 hours of pre-arranged 1-2-1 meetings and over 12 hours of networking, don't miss the opportunity to connect with 1,000 leaders from across pharma, biotech, regulatory and academia.

Engaging Thought Leadership
Experience over 30 hours of interactive discussions, thought leadership debates, and collaborative roundtables, with insights from industry leaders to benchmark your research & development pipeline.

Global Technology Showcase
An international exhibition showcasing cutting-edge technologies and services from premier providers in the scientific field.

Networking Emphasis
Unparalleled networking opportunities, including personalised 1-2-1 meetings, a start-up zone, vibrant drinks reception, and informal gatherings to foster meaningful connections.

Start-up Zones & Awards Ceremony
Inspiring poster displays and presentations unveiling the latest breakthroughs from emerging biotech, pharma, and start-up companies.

NextGen Biomed - What to Expect Image 1
NextGen Biomed - What to Expect Image 2
NextGen Biomed - What to Expect Image 3
1000

leading pharma, biotech, regulatory & academic delegates

230
hours of pre-arranged 1-2-1 meetings, facilitating business growth
30
hours of presentations, discussions & interactive content
13
hours of networking breaks, including speed networking & refreshments

NextGen Biomed 2025 Programme Highlights

Explore dynamic panels, engaging roundtables, and hands-on workshops designed to drive innovation and foster collaboration, including:

Proteins, Antibodies & ADCs
Panel Discussion: What Is The Next Game Changer In Antibody Engineering?

Moderator: Karen Silence, Head Preclinical Product Development, ArgenX
Panellists include Berit Olsen Krogh, Senior Research Fellow; and Lundbeck Andrew Buchanan, Principal Scientist, AstraZeneca

Peptides
Roundtable: Regulatory Insights On Bringing A Peptide To Human Trials

Moderator: Paul Reid, Co-Founder & Chief Scientific Officer, Celtic Bio

Oligonucleotides
Workshop: Development Of Targeted Delivery Systems

Two Presentations, followed by a Panel Discussion on 'The Next Chapter Of Oligonucleotide Delivery'
Moderator: Steve Hood, Senior Director, Oligonucleotide ADME Strategy, GSK

Sustainability in Tides & Biologics
Panel Discussion: Navigating The Paradigm Shift Towards Greener Approaches

Moderator: Walter Cabri, Full Professor of Organic Chemistry, University of Bologna
Panellists include Daniel Sejer Pedersen, Chemical Development Specialist CMC API Development, Novo Nordisk;
Anna Maria Papini, Full Professor & Group Leader, University of Florence;
Louis Diorazio, Senior Principal Scientist, New Modalities, AstraZeneca;
Alessandra Tolomelli, Associate Professor, University of Bologna

Immunotherapy & Immuno-oncology
Presentation: How The RNA Technologies Could Help To Prevent Infectious Diseases And Could Be Applied To Various Chronic Disease Immunotherapies?

Presented by: Daniel Larocque, Innovation Lead, Innovation and Emerging Science, Sanofi

Who is Speaking at NextGen Biomed 2025?

Anna Perdrix
Founder & Co-Chief Executive Officer,
Sixfold Bioscience
Fernando Albericio
Professor,
University of KwaZulu-Natal
Joel Richard
Chief Development Officer,
Enterome
Kelly Loyet
Distinguished Scientist,
Genentech
Livija Deban
Chief Scientific Officer,
Prokarium
Maria Koufali
Director,
UK Vaccine Innovation Pathway
Marta Amaral
Group Head High Throughput Protein Engineering in Large Molecules Research,
Sanofi
Martina Ochs
Project Leader,
CEPI
Philip Beer
Chief Scientific Officer,
Step Pharma
Rick Hibbert
Vice President & Head of CMC Science & Technologies,
Genmab
Sudhir Agrawal
President & Founder,
ARNAY Sciences
Tristan Vaughan
Vice President Protein Engineering,
Immunocore
Aaron John Balana
Scientist III,
Genentech
Aikaterini Gatsiou
Assistant Professor,
Lancaster University
Ajan Reginald
Chief Executive Officer,
Roquefort THerapeutics PLC
Alain Wagner
Director,
Strasbourg University
Alastair Lawson
Vice President and Immunology Fellow,
UCB
Alessandra Tolomelli
Associate Professor,
University of Bologna
Alessandro Gori
Group leader,
National Research Council of Italy
Alexandria Cogdill
Head of Strategic Initiatives, Global Business Development,
Daiichi Sankyo, Inc
Alexey Rak
Head of Bio Structure and Biophysics,
Sanofi
Álvaro Enríquez García
Medicinal chemist,
Eli Lilly
Amita Vaidya
Principal Scientist,
Sanofi
Ammar Ahmed
Senior Scientist,
Imperial College London
Amy Li
Director, Drug Discovery,
T-Therapeutics Ltd
Andreas Reichel
Vice President, Head PMS,
Bayer AG
Andreas Midbøe Hoff
Head of In Silico & AI Department,
Nykode
Andrew Slee
Chief Operating Officer,
Protagenic Therapeutics
Andrew Jamieson
Professor,
University of Glasgow
Andrew Buchanan
Scientist,
AstraZeneca
Andri Vasou
Senior Research Scientist,
Bioarchitech
Aneesh Karatt-Vellatt
CoFounder & CSO,
Maxion therapeutics
Anna Hine
Professor of Protein Engineering,
Aston University
Anna Maria Papini
Full Professor and Group leader of PeptLab,
University of Florence (Italy)
Annelise Vuidepot
Chief Technology Officer,
Immunocore
Ash Otter
Principal Investigator, Emerging Pathogen Serology,
UKHSA
Baldur Sveinbjørnsson
Chief Scientific Officer,
Lytix Biopharma
Bassam Hallis
Deputy Director of Research and Evaluation,
ukhsa.gov.uk
Benjamin Lindner
Data Scientist,
Boehringer Ingelheim RCV GmbH & Co KG
Berit Olsen Krogh
Senior Research Fellow,
Lundbeck
Bernard Maillere
Head of laboratory,
CEA
Bishnu Nayak
Senior Director,
NeologicsBio
Bjorn Onfelt
Professor of Applied Physics,
Royal Institute of Technology
Brian Schanen
Global Head,
Sanofi
Bryce Nelson
Head Protein and Antibody Engineering,
Orion
Callum Scott
Head of Development,
Scancell
Carla Vinals
Vice President, Global Regulatory Product Strategy,
Moderna Therapeutics
Carol Sze Ki Leung
Senior Immunologist,
Ludwig Institute, Oxford University
Caroline Lonez
R&D Associate Director,
Celyad
Charlotte Vernhes
Scientific and Medical Affairs Director,
Vaccines Europe
Chris Hart
Chief Executive Officer,
Creyon Bio
Christian Garde
Director,
Evaxion Biotech
Christine Dr. Rothe
Chief Development Officer (CDO),
Iomx Therapeutics Ag
Christopher Scott
Professor,
Queen's University Belfast
Christopher Coxon
Senior Lecturer, Medicinal Chemistry,
THE UNIVERSITY OF EDINBURGH
Chun Kong Mak
Oligonucleotides Analytical Scientist,
Synthon
Claudia Masini D'Avila
Principal Scientist,
Sanofi - Ghent
Dan Swerdlow
Senior Director,
GSK
Dan Hardy
CEO,
Microsol Ltd
Daniel Larocque
Innovation Leader,
Sanofi Vaccines
Daniel Fonseca
Senior Scientist,
Immunocore
Daniel Sejer Pedersen
Specialist,
Novo Nordisk A/S
Darko Skegro
Associate Director,
Novartis
David Craik
Professor,
The University of Queensland
David Evans
Chief Scientific Officer,
Sirnaomics
David Brockwell
Professor,
University of Leeds
David Pejoski
Co-founder & CEO,
Adoram
David Wraith
Professor of Immunology, Director of the Institute of Immunology and Immunotherapy,
University of Birmingham
Denise Steckel
Head of Clinical Collaborations Development,
Genentech
Ed Tate
Professor,
Imperial College London
Eef Dirksen
Group Leader,
Byondis B.V.
Elisa Marelli
Research Scientist,
Scancell
Emma Grant
Senior Analytical Development Scientist,
Immunocore
Emma Stanley
Director, Program Lead - Head of Antibody Discovery,
Mestag Therapeutics
Erik Vernet
Vice President - Scientific Data Registration,
Novo Nordisk
Fazel Shabanpoor
Lab Head Peptide And Oligonucleotide Therapeutics,
The Florey Institute of Neuroscience and Mental Health
Felix Schumacher
Program Leader Targeted Therapeutics,
Hoffmann La Roche Ltd
Francisca Wollerton
Senior Director of Protein Engineering and Novel Modalities,
AstraZeneca
Francisca Wollerton
Senior Director of Protein Engineering and Novel Modalities,
AstraZeneca
Gabriel Wong
Senior Director Physician, Clinical Research, Immunology,
AstraZeneca
Gal Gur
VP Business Development,
Anima Biotech
Georgios Skretas
Director, Institute for Bioinnovation,
Biomedical Sciences Research Center "Alexander Fleming"
Giulio Russo
Senior Scientist,
Merus NV
Hans Melo
Chief Executive Officer,
Menten Biotechnology Labs
Hans Van Der Vliet
Chief Scientific Officer,
LAVA Therapeutics
Helen Bright
Chief Scientific Officer,
Centauri Therapeutics
Helene Kaplon
Translational Scientist,
Servier
Henry Maun
Staff Scientist,
Genentech
Hester Van Zeeburg
PM immunomonitoring,
Mendus AB
Ian Hamley
Professor of Physical Chemistry,
University of Reading
Ijeoma Uchegbu
Professor of Pharmaceutical Nanoscience,
University College London
Ilaria Poledri
Co-Founder,
ExCulture
Immanuel Lerner
Chief Executive Officer,
Pepticom
Isabelle Sermadiras
Associate Principal Scientist,
AstraZeneca
Iulia Oita
CMC manager,
Ziphius Vaccines
Janos Tibor Kodra
Principal Scientist,
Novo Nordisk
Jean Ge
Patent Attorney,
Wolf Greenfield
Jenny Fitting
Head of AAV and Protein Science,
Bayer
Jill Walker
Immuno-Oncology Diagnostic Franchise Leader, Precision Medicine & Genomics,
AstraZeneca
John Maher
Chief Scientific Officer,
Leucid Bio
Jonathan Kwok
Chief Executive Officer,
Infinitopes
Joost Uitdehaag
Head of Biology,
Crossfire Oncology
Jordan Davies
Campaigns,
Oxford Global
Jörg Wischhusen
Professor,
University Hospital Würzburg
Jutta Eichler
Professor,
University of Erlangen-Nurnberg
Karen Silence
Head Preclinical Product Development,
Argenx BVBA
Kate Smith
Senior Director, Head of UK Protein and Cell Sciences,
GSK
Kerry Chester
Professor,
UCL
Kevin Fitzgerald
Chief Scientific Officer,
Epsilogen
Kevin Maskell
Research Director,
Bioarchitech
Kirsty Crame
Vice President Clinical Strategy & Development,
Medigene AG
Knud Jørgen Jensen
Professor,
Copenhagen University
Komal Kedia
Associate Principal Scientist,
Merck US
Kuda Muchandibaya
Lecturer for Supply Chain Management & Logistics,
Rhine-Waal University of Applied Sciences
Laura Starkie
Director,
UCB
Laura Collins
Director Bioinformatics,
Immunocore
Leonardo De Maria
Principal Scientist,
AstraZeneca
Louis Diorazio
Senior Principal Scientist,
AstraZeneca
Lucia Ferrazzano
Junior Assistant Professor,
University of Bologna
Luis Gómez-Morales
Scientific Project Manager,
Pepkon
Mads Hald Andersen
Professor, VP,
IO Biotech
Mani Mudaliar
Director, Quantitative Biomarkers,
Exscientia
Marc Vendrell
Professor of Translational Chemistry,
University of Edinburgh
Maria Fawaz
Associate Principal Scientist,
Merck & Co., Inc., Kenilworth, New Jersey, U.S.A.
Maria DeBruin
Director, Analytical Research and Development,
MSD
Marie McAvoy
Chief Scientific Officer,
Nanosyrinx
Marina Fedorova
Scientific Investigator,
GSK
Mark Eccleston
Chief Executive Officer,
ValiRx Plc.
Mathieu Cinier
Scientific Director,
Affilogic
Matthew Burrell
Associate Director,
AstraZeneca
Mattias Malm
Senior Scientist,
Ferring Pharmaceuticals
Micaela Graglia
Analytical Chemist, Molecular Design,
Silence Therapeutics
Michael Dyson
Vice President,
Ichnos SA
Michael Delaney
Principal Scientist,
NovoNordisk
Michal Shoshan
Founder & Chief Executive Officer,
metaLead Therapeutics AG
Mihaela Bozic
Scientist,
T-Therapeutics
Mikhail Kuravskiy
Principal Scientist,
UCB
Morten Lindow
RNAHub Founder & Mission Lead,
Roche
Nadim Akhtar
Senior Principal Scientist, New Modalities,
AstraZeneca
Nazneen Dewji
Chief Executive Officer,
Cenna Biosciences
Nesrine Chakroun
Associate Director,
Merus NV
Norbert Furtmann
Sanofi,
Head of AI Innovation NANOBODY® Platform
Obinna Ubah
Principal Scientist,
Elasmogen Limited
Owen Vickery
Associate Principal Scientist in augmented biologics,
Astrazeneca
Patricia Alves
Head of the Sanofi Satellite Lab & Coordinator of Analytical Services Unit and Mass Spectrometry Unit,
Instituto de Biologia Experimental e Tecnológica
Paul Wassmann
Senior Principal Scientist,
Novartis AG
Paul Reid
Chief Scientific Officer,
Celtic Biotech
Paul Skipp
Professor of Proteomics,
University of Southampton
Pawel Stocki
Vice President R&D,
Ossianix
Pete Gough
Chief Scientific Officer,
Nimble Therapeutics
Peter Ellmark
CSO,
Alligator Bioscience
Peter Sondermann
CEO,
Tacalyx GmbH Privacy Policy Imprint
Prasun Chakraborty
Chief Executive Officer and Founder,
Genevation LTD
Rajika Perera
Chief Executive Officer,
Poseidon LLC
Raymond Tesi
President & Chief Executive Officer,
InMune Bio
Reeta Daswani
Senior Scientist,
Sixfold
Rita Martello
Scientific Director, NBE DMPK Lead,
Merck KGaA
Rodrigo Abreu
Principal Scientist,
LifeArc
Sagar Kathuria
Biophysicist - Protein Engineering,
Sanofi
Sandeep Talapatra
Science Lead - Protein Science,
GSK
Sandor Batkai
Co-founder, Head of Medical Research and Intelligence,
Cardior Pharmaceuticals GmbH
Sandra Tremmel
Microbiology Engineer, Pharma Technical Product Quality- Analytical Sciences,
F. Hoffmann-La Roche Ltd
Sandrien Janssens
CMC Director,
Mosanna Therapeutics
Santiago Parpal
Principal Scientist,
Sprint Bioscience
Sara Mangsbo
Chief Innovation Officer,
Ultimovacs
Sarah Stuart
HTC Team Leader,
GSK
Sarah Hindson
Senior Scientist,
GSK
Saul Martinez Montero
Senior Director, RNA Therapeutics,
Dyne Therapeutics
Saurabh Sen
Associate Director, Cell Line Development, Mammalian Platform Biologics,
Sanofi
Simon Krah
Associate Director,
Merck Healthcare KgaA
Simon Plyte
Chief Scientific Officer,
Biomunex Pharmaceuticals
Simon Hufton
Section Head Molecular Immunology, Division of Biotherapeutics,
MHRA
Sonia Macia
Chief Medical Officer,
Aromics Therapeutics
Sophia Karagiannis
Professor of Translational Cancer Immunology and Immunotherapy,
King's College London
Sritama Bose
Head of Chemistry Research and Innovation,
Nucleic Acid Therapy Accelerator MRC
Stefan Z
Senior Director - Global Head of Antibody Discovery & Protein Engineering,
Merck Kgaa Darmstadt Germany
Stephen Miller
Principal Scientist,
Genentech
Stephen Sullivan
Chief Operating Officer,
iPSirius
Steve Hood
Senior Director, Oligonucleotide ADME Strategy, DMPK,
GSK
Steven Schmitt
Co-Founder & Chief Executive Officer,
Myria Biosciences
Stine Friis Thorsen
Director Clinical Development,
Evaxion Biotech
Sue Charlton
Head of Clinical Evaluation,
UKHSA
Talip Ucar
Senior Director - AI Research,
AstraZeneca
Tatyana Ponomaryov
Principal Scientist,
Plasticell Limited
Thomas Kraft
Principal Scientist,
Roche
Tim Hickling
Immunogenicity Expert Scientist,
Roche
Tomáš Hanke
Professor,
University of Oxford
Tomasz Witkos
Associate Director,
AstraZeneca
Trevor Smith
Vice President,
Inovio
Vincent Dewar
Head of Immunoassay,
GSK
Vincenzo de Filippis
Associate Professor Biochemistry,
University of Padova
Vladimir Gligorijević
Senior Director, AI/ML,
Genentech
Walter Cabri
Professor,
University of Bologna
Wen Chang
Associate Vice President Discovery and Early Development,
AcuraStem
Will Nesbit
Director - Process Chemistry, CMC,
Bicycle Therapeutics
Wolfgang Koch
Senior Scientist,
F-star Therapeutics Inc
Xiao Wan
Senior Researcher - Biology,
Nucleic Acid Therapy Accelerator (NATA)
Yann Abraham
Associate Director AI for Single Cell,
Johnson & Johnson Innovative Medicine
Yi Yang
Principal Scientist,
Ferring Pharmaceuticals A/S
Zahra Rattray
Senior Lecturer,
University of Strathclyde

Speakers

Speakers of Cell 2024 Included:

Anna Nowocin
Head of Flow Cytometry Standardisation,
MHRA
Charlotte Serra
Vice President, Head of Quality Assurance, Cellular Therapy,
Galapagos
Emma Chan
Director of Process Development,
Orchard Therapeutics
Esther Kitto
VP Clinical Operations,
Resolution-Tx
Ibon Garitaonandia
Chief Scientific Officer,
CellProthera
Kirsty Crame
Vice President Clinical Strategy & Development,
Medigene AG
Kyle Zingaro
Head of Gene Therapy Process Sciences,
UCB
Lindsay Davies
Chief Scientific Officer,
NextCell Pharma AB
Muhammad Akram
Senior Medical Director,
Legend Biotech
Rolf Koehler
Associate director,
Novartis
Ruben Rizzi
Senior Vice President Global Regulatory Affairs,
BioNTech SE
Tim Allsopp
Chief Technology Officer,
Laverock Therapeutics
Adam Sidaway
Lead Scientist - Molecular Biology,
Uncommon
Aisling McMahon
Professor of Law,
Maynooth University
Ajan Reginald
Chief Executive Officer,
Roquefort THerapeutics PLC
Akihiro Ko
Chief Executive Officer,
Elixirgen Therapeutics Inc
Alex Smith
Director Regulatory Science,
HoganLovells LLP
Aline Miller
Principal Investigator, Professor of Biomolecular Engineering and Associate Dean for Business Engagement and Innovation,
University of Manchester
Amir Hefni
Chief Executive Officer,
Resolution Therapeutics
Anton Hutter
Partner, Patent Attorney,
Venner Shipley IP
Athanasios Didangelos
Director, Pharmacology,
Complement Therapeutics Ltd
Benedikt Berninger
Professor,
King's College London
Benjamin Taylor
Director,
AstraZeneca
Catia Andreassi
Director,
AviadoBio
Charlotte Wilding
Patent Attorney,
Venner Shipley
Chris Middendorf
Senior Director Pharma and Biotech GMP Compliance,
HoganLovells, LLP
Chrysanthi Sitmalidou
Scientist II,
Orchard Therapeutics
Darius Widera
Professor of Stem Cell Biology and Regenerative Medicine,
University of Reading
Darren Nesbeth
Associate Professor,
UCL
Djordje Djordjevic
Co-founder + CEO,
Plurify
Dolores Schendel
Chief Scientific Officer,
Medigene AG
Elena Piletska
Associate Professor in Bioanalytical Chemistry,
University of Leicester
Eleonora Zucchelli
Associate Lead Scientist,
Cell and Gene Therapy Catapult
Eli Gilsohn
VP, Intellectual Property,
Resolution Therapeutics
Emilie Gauthy
Head of CMC,
Zelluna Immunotherapy
Farhad Paylakhi
Co-Founder & Vice President of R&D,
64x Bio
Gabriel Kent
Analytical Development Scientist,
Resolution Therapeutics
Harris Makatsoris
Professor,
King’s College London
Himansu Patel
Head of Quality Innovation,
Cell & Gene Therapy Catapult
James Carlson
Principal Safety Director ATMP Enablement,
Roche
Jas Uppal
Founder and CEO,
BQP Consultancy
John Garcia
Head of New Manufacturing Technologies,
UCL
John H Wolfe
Professor,
Child Hosp Philadelphia
Jose Bonafont Arago
Senior Scientist,
DanausGT
Kirthika Sreenivas
Senior Scientist,
Polpharma Biologics
Klara Kulenkampff
Project Manager,
Bayer
Leila Abbas
PreClinical Manager,
Rinri Therapeutics
Lucy Williams
Partner,
J A Kemp LLP
Lucy Barnes
Patent Attorney,
J A Kemp
Luis Ayala
Scientist Perfusion Systems,
Merck KGaA
Luz Alonso-Crisostomo
Senior Scientist,
AstraZeneca
Mahdieh Hassanjani
Innovation Project Manager,
Cell and Gene Therapy Catapult
Manuel Carrondo
senior vp,
IBET
Marc Schneider
Director Product Supply,
BioNTech SE
Marcel van Houten
Director Global Supply Chain,
Orchard Therapeutics Ltd
Maria Luisa Giorello
Global Gene Therapy Platform Enablement Director,
Pfizer Ltd
Marina Tarunina
Research Director,
Plasticell Ltd
Martin Dass
Scientist,
Boehringer Ingelheim Pharma GmbH & Co. KG
Matthew Gibson
Professor,
University of Manchester
Matthew Garner
Head of Intellectual Property,
Catapult
Menasheh Fogel
IT Head, Cell and Gene Therapy,
Bayer
Millie Fox
Senior Scientist,
AstraZeneca
Molly Stevens
John Black Professor of Bionanoscience,
University of Oxford
Monica Raimo
Sr. R&D Manager,
Glycostem Therapeutics
Nabiha Saklayen
CEO & Co-Founder,
Cellino
Nicolas Weber
Quality Team Leader QC,
Novartis Pharma
Nirai Govindasamy
Senior Scientist,
Bluu Seafood
Nitin Garg
Director, CMC product lead,
Adaptimmune
Patricia Mendoza
Senior Scientist,
AstraZeneca
Patrizia Ferretti
Professor of Regenerative Biology,
University College London
Philippe Henon
Chairman,
CellProthera SAS
Rahul Khetan
Venture Capital Associate,
UCB Ventures
Raiko Stephan
Gene and Cell Therapy Lead,
Novartis
Roelof Rongen
Chief Executive Officer,
Adolore BioTherapeutics
Roshni Desai
Nonclinical Assessor,
MHRA
Sakis Mantalaris
Professor,
Trinity College Dublin & NIBRT
Sally Gu
Senior Associate,
Hogan Lovells
Sam Goldsmith
Head of Commercialisation of Research & Investments,
CGT Catapult
Sarah Howlett
Associate Director,
AstraZeneca
Sergey Piletsky
Professor in Bioanalytical Chemistry,
University of Leicester
Simon Chandler
Chief Executive Officer,
Rinri Therapeutics
Stephen Sullivan
Chief Operating Officer,
iPSirius
Sujith Sebastian
Viral Vector Hub Manager,
NHSBT
Terri Gaskell
Chief Technical Officer,
Rinri Therapeutics
Ulrich Rümenapp
Senior Biotech Program Lead,
Bayer AG
Uwe Buecheler
Senior Advisor - Biopharmaceuicals,
Boehringer Ingelheim
Vicki Coutinho
Managing Director,
Geni Consulting
Volker Huppert
Chief Development Officer,
Glycostem Therapeutics B.V.
Xavier Fontana
Principal Scientist,
Adaptimmune

Interested in Sponsoring Cell 2025?

Become a driving force in connecting leaders from every stage of the value chain to drive advanced therapy development & novel biologics processing. Cell 2025 offers a unique platform to enhance your brand visibility and connect with thousands of pharma, biotech, and R&D experts. Our branded event opportunities, immersive experiences, and content services enable you to engage, educate, and collaborate with the community shaping the future of biomedicine today.


Interested in Sponsoring NextGen Biomed?

Become a driving force in accelerating the next generation of biologics and immunotherapy medicines to patients. NextGen Biomed offers a unique platform to enhance your brand visibility and connect with thousands of pharma, biotech, and R&D experts. Our branded event opportunities, immersive experiences, and content services enable you to engage, educate, and collaborate with the community shaping the future of biomedicine today.

2025 Sponsors Include

GenScript

The 1-2-1s are the best thing about Oxford Global events, well organised and good number of relevant contacts. Good high level contacts from big companies.

 

Advanced Therapies Specialist Team Leader,
Genscript

Biosystems Acro

Biologics 2024 has been one of the best events I have attended so far in my career.

 

Territorial Sales Manager UK,
ACROBiosystems Co., Ltd.

Bioassay

 

Impressed by the effort to bring people together.

 

Business Development Director,

Bioassay

IpA

 

Nice set-up, with good support for exhibitors

 

Director of Client Relations,

ImmunoPrecise

New Opportunities

The Start-up Zone

The start-up zone provides a unique opportunity to for you to exhibit, network, and pitch to our global audience of pharma, biotech, and investment professionals. 

It's designed for start-ups from across the biologics space, working on cutting-edge therapies, innovative platform technologies, products, and solutions and is an ideal platform to share your business plans. 

There are two options, based on the size of your organisation with prices starting from £1,500 (+VAT). 

For further information and to get started submit the application form below.

Criteria:

To qualify your company must be:

  • Therapeutic Start-Up, Emerging Technology OR Service Start-Up
  • Operating No More Than 5 Years
  • 0 – 30 employees
  • Pre-Series A Funding

 

Successful applications receive:

  • 1 Full Conference Pass
  • 10-Minute Presentation Opportunity
  • 1x1m Space in Start-Up Zone
  • Logo Featured on Event Website & App as a Participating Start-Up
  • Ability to Arrange Peer to Peer Meetings via the Congress App

2025 Best Poster Presentation Competition & Award

The NextGen Biomed Best Poster Presentation Competition & Award includes the best poster presentation award and is intended to honour an outstanding individual performance for a scientific work by either an early career or established scientist, including PhD student and PostDocs.  

Please submit your poster presentation by no later than 13th January 2025 in the below category:

  • Protein/Antibody Engineering
  • Bioanalysis & Characterisation
  • Next Generation Biotherapeutics
  • Peptides Chemistry & Therapeutics
  • Oligonucleotides Chemistry & Therapeutics
  • Sustainable Chemistry & Manufacturing
    • Open to all scientists, including students (PhD), PostDocs, and established researchers representing pharma & biotech companies and/or academic institutions  
    • Applicants must be the first AND presenting author of the submitted paper and register for the meeting by 13th January 2025 
    • ONLY ONE submission per person will be accepted. If authors submit multiple abstracts for consideration for the competition, only one abstract will be taken into consideration  

Applicants must follow the procedure as follows:  

  • Register and submit an abstract by 13th January 2025 using the registration link to the right on this page. Please ensure you add the poster display option on the registration page to secure your admission into the Best Poster Competition & Award
  • Once registered you will be provided with the online abstract submission form  
  • Prepare the poster or platform and present it (The poster presenter should be at the poster during all breaks.)  
  • The winner with the highest scores will be announced at the Morning Networking Break on Day 3 of the event  

The poster presentations will be evaluated by everyone attending the event on the basis of originality of the approach and quality of the work (e.g. appropriate methodology, interpretation of results, conclusiveness). Attendees will be allowed to cast one vote by selecting their favourite work in the poster area. All votes will be counted at the end of Day 2 at 5pm and results will be announced during the morning networking break on Day 3. .

The winners receiving the highest scores will be announced at the Morning Networking Break on Day 3 and will be given a trophy as well as £600 contribution towards travel & accommodation costs to attend the 2026 NextGen Biomed event. Oxford Global will also provide winners with PLUS Pass – 12 months access to our digital content platform providing access to on-demand presentations, exclusive reports and highlights.  

Plan Your Visit

Full details regarding accommodation, travel directions, health and safety, and other logistical information for the event will be added here in the coming months.

Interested in Cell 2025?